- February 2025: $221.80 (post-GLP-1 drug concerns)
- March 2025: $238.60 (recovery momentum begins)
- May 2025: $244.98 (strong Q3 results)
- July 2025: $284.89 (Q4 earnings beat)
- August 2025: $293.73 (approaching all-time highs)
How to Buy ResMed Inc. (RMD) Shares - Investment in ResMed Inc. (RMD) Stock
Updated on 25 Aug 2025
Thinking about owning a piece of the healthcare technology revolution? ResMed Inc. (RMD) is transforming how millions breathe and sleep better worldwide. This medical device leader combines innovation with profitability—perfect for investors seeking growth in the essential healthcare sector. Let's explore why RMD deserves your attention and how to make it part of your portfolio.
Article navigation
- 📈 ResMed Stock: Current Price and Market Position
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy ResMed Inc. (RMD) Shares – Step by Step
- 💡 Why Pocket Option Fits Healthcare Investors
- 🌍 ResMed in 2025: Healthcare’s Digital Pioneer
📈 ResMed Stock: Current Price and Market Position
As of August 25, 2025, ResMed Inc. (RMD) trades at $293.73 on the NYSE. The stock is currently dancing near its 52-week high of $293.81, showing remarkable strength in the healthcare technology space.
Mark your calendar: October 23, 2025 is your next critical date. That’s when ResMed releases its Q1 2026 earnings report. Historically, these quarterly announcements create significant price movements.
How Earnings Reports Move RMD Stock
Looking at recent history reveals a clear pattern:
| Date | Event | Pre-News Price | Post-News Change |
|---|---|---|---|
| Jul 31, 2025 | Q4 FY2025 Earnings | $284.89 | +3.1% (beat estimates) |
| Apr 23, 2025 | Q3 FY2025 Earnings | $275.16 | +2.8% (strong growth) |
| Jan 2025 | Q2 FY2025 | $260.50 | +5.6% (margin expansion) |
| Oct 2024 | Q1 FY2025 | $248.20 | +4.9% (new product launch) |
| Jul 2024 | Q4 FY2024 | $235.80 | +5.2% (record revenue) |
Trend Insight: ResMed consistently delivers positive surprises, with earnings beats typically driving 3-6% immediate gains. The company has beaten EPS estimates in 8 of the last 10 quarters, creating reliable momentum around reporting dates.
6-Month Price Journey (February-August 2025)
ResMed shares delivered an impressive 32.5% return over the past six months:
Why the powerful climb?
- 10% revenue growth in Q4 FY2025 to $1.35 billion
- 19% operating profit increase to $454.5 million
- Dual Red Dot Design Awards for innovative products
- Strong institutional confidence with insider activity
🔮 Price Forecast: 2025-2030 Outlook
Short-Term Projections (2025-2026)
- 2025 Year-End: $310-325 (continued innovation momentum)
- 2026 Target: $340-360 (market expansion and SaaS growth)
Medium-Term Vision (2028)
Analysts project $270-275 range based on current trajectories, though this appears conservative given the company’s innovation pace and market leadership position.
Long-Term Growth (2030)
With the global sleep apnea market expected to reach $9.8 billion by 2030 and ResMed’s digital health expansion, $450-500+ represents a realistic long-term target.
Verdict: STRONG BUY for long-term investors. Current valuation reflects strong fundamentals with room for multiple expansion as digital health adoption accelerates.
⚠️ Key Risks vs. Positive Signals
Risks to Consider
- GLP-1 Drug Competition: The biggest narrative risk – weight loss drugs could potentially reduce sleep apnea prevalence (Analyst Report)
- Regulatory Changes: Healthcare policy shifts could affect reimbursement rates
- Supply Chain Volatility: Global manufacturing and distribution challenges
- Currency Exposure: 58% international revenue creates FX risk
Green Lights for 2025-2026
- Innovation Leadership: 10,000+ patents and dual Red Dot Awards in 2025
- Digital Health Expansion: SaaS segment growing at 20%+ annually
- Aging Population: Demographic trends favor respiratory care demand
- Strong Financials: 27.22% net profit margin and $1.2B+ free cash flow
🛡️ What Should a Beginner Trader Do Today?
- Start Small: Begin with a position representing 2-5% of your portfolio
- Dollar-Cost Average: Add on dips, especially around the October earnings
- Set Price Alerts: Buy if RMD pulls back to $280-285 support levels
- Think Long-Term: This is a 3-5 year growth story, not a quick trade
Humorous veteran wisdom: “Trading RMD is like using their CPAP machines – consistency brings the best results, and panicking during temporary breathing difficulties only makes things worse!”
✅ How to Buy ResMed Inc. (RMD) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NYSE-listed stocks and competitive fees |
| 2 | Complete account funding | Start with an amount you’re comfortable risking |
| 3 | Search “RMD” ticker | Use the exact symbol, not just “ResMed” |
| 4 | Select order type | Limit orders prevent overpaying during volatility |
| 5 | Review and confirm | Check commission rates and settlement details |
💡 Why Pocket Option Fits Healthcare Investors
Pocket Option offers unique advantages for building a medical technology portfolio:
- Minimum deposit: $5 – Test healthcare sector strategies with minimal risk
- Rapid verification – Start trading within minutes with simple document upload
- Global access – Trade US healthcare stocks from anywhere worldwide
- Educational resources – Learn about medical technology investing on the Pocket Option blog
🌍 ResMed in 2025: Healthcare’s Digital Pioneer
ResMed dominates the $7 billion sleep and respiratory care market with revolutionary cloud-connected devices and AI-powered software platforms. The company’s integrated approach – combining hardware with digital health solutions – positions it perfectly for the home-based healthcare revolution.
2025 Innovation Highlight: ResMed’s AirTouch™ N30i nasal cradle mask won dual Red Dot Design Awards, featuring a revolutionary fabric-silicone cushion that improved patient comfort by 40% compared to previous models. The company now holds over 10,000 patents and designs, cementing its innovation leadership.
FAQ
Is ResMed a good long-term investment?
Absolutely. With an aging global population, increasing sleep disorder awareness, and the shift toward home-based healthcare, ResMed's integrated device-plus-software model positions it for sustained growth. The company's 27% net margins and continuous innovation make it a strong candidate for long-term portfolios.
What's the biggest risk facing RMD stock?
The GLP-1 weight loss drug narrative represents the most significant near-term risk. While these drugs show promise for obesity-related sleep apnea, ResMed's devices remain essential for moderate-to-severe cases and broader respiratory conditions beyond sleep apnea.
How often does ResMed pay dividends?
ResMed pays quarterly dividends. The most recent declaration had a record date of August 14, 2025, payable on September 18, 2025. The company has maintained consistent dividend payments while reinvesting heavily in growth.
What percentage of revenue comes from international markets?
Approximately 42% of ResMed's revenue comes from international markets outside the U.S., Canada, and Latin America. This global diversification provides stability but also exposes the company to currency exchange fluctuations.
How does ResMed's digital health platform work?
ResMed's cloud-connected devices transmit usage data to healthcare providers through platforms like AirView, enabling remote patient monitoring, treatment adherence tracking, and personalized therapy adjustments without office visits. This SaaS segment is growing rapidly and improving patient outcomes.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.